{"id":12116,"date":"2025-03-13T21:39:55","date_gmt":"2025-03-13T20:39:55","guid":{"rendered":"https:\/\/valintermed.com\/?p=12116"},"modified":"2025-03-13T21:39:55","modified_gmt":"2025-03-13T20:39:55","slug":"mukopolisaharidoz-2-tipa-mps-ii-sindrom-hantera","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/mukopolisaharidoz-2-tipa-mps-ii-sindrom-hantera\/","title":{"rendered":"Mucopolysaccharidosis type 2 (MPS II, Hunter syndrome)"},"content":{"rendered":"
<\/div>\n

Mucopolysaccharidosis type 2 (MPS II, Hunter syndrome) is a hereditary disease caused by a deficiency of a specific enzyme, iduronidase, which is involved in the breakdown of glycosaminoglycans. Deficiency of this enzyme leads to the accumulation of glycosaminoglycans in various tissues and organs, which causes progressive disorders in many body systems. Symptoms of the disease can vary from mild to severe, accompanied by disorders of the respiratory system, cardiovascular system, musculoskeletal system and nervous system. In most cases, MPS II is diagnosed in the early stages of development, but manifestations may become apparent only as the disease progresses, which requires careful monitoring and timely intervention.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n